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Background: The aim of this study was to assess whether serology and spirometry and the combination of both
can complement culture-based detection for earlier recognition of Pseudomonas aeruginosa infection in children
with cystic fibrosis.
Methods: A 4 year longitudinal prospective study that included 67 Slovenian children with cystic fibrosis with a
mean age of 10.5 years was conducted. Serology, spirometry and a scoring system combining serology and
spirometry were assessed and compared. Infection was confirmed with isolation of Pseudomonas aeruginosa
from respiratory samples.
Results: There was a significantly positive correlation between serology and the combination of serology and
spirometry and Pseudomonas aeruginosa isolation (P < 0.01 for both) and a significantly negative correlation
between spirometry and Pseudomonas aeruginosa isolation (P < 0.05). An increase in serology for 1 ELISA unit
increased the possibility of Pseudomonas aeruginosa isolation 1.6 times. A fall in FEV1% predicted for 10%
increased the possibility of Pseudomonas aeruginosa isolation 9.8 times. Binary logistic regression analysis was
used to determine the odds ratios and 95% confidence intervals for all three approaches. Serology had the
highest specificity (0.80) and the combination of serology and spirometry the highest sensitivity (0.90). Both had
a high negative predictive value (0.93 and 0.79 respectively).
Conclusion: Using serology and the combination of serology and lung function measurement can be beneficial
for earlier detection of infection with Pseudomonas aeruginosa in children with cystic fibrosis when done
simultaneously with standard culture-based detection from respiratory samples.
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Chronic infection with Pseudomonas aeruginosa (P. aer-
uginosa) is a known cause of increased morbidity and
mortality in patients with cystic fibrosis (CF) [1–4]. Early
detection of P. aeruginosa infection enables early anti-
biotic therapy and enhances the chances of successful
eradication. Detection of every new infection with P.
aeruginosa is important – in never infected patients the
first infection, in intermittently infected a new infection
after successful eradication and in chronically infected
an infection with a new non-mucoid strain of P. aerugi-
nosa [2, 5–7]. When P. aeruginosa remains in the lungs
of CF patients for longer periods, the strains change to
mucoid type, which makes eradication practically impos-
sible [1, 2, 8]. To evaluate the presence of P. aeruginosa
in the lower airways, culture-based detection is preferably
carried out from samples that reflect microbiota mostly
from the lower airways such as sputum or bronchoalveo-
lar lavage (BAL) [9–11]. Sputum is usually produced in
patients with progressive CF or those that are in ex-
acerbation and acquisition of BAL in children requires
bronchoscopy under general anesthesia. In non-sputum-
producing CF patients induced sputum has been shown
to improve detection of pathogens, including P. aerugi-
nosa [12]. Induced sputum can be difficult to acquire in
children under the age of 5 years and in such instance can
be replaced by deep throat aspirates or swabs [13].
Although deep throat swabs and aspirates are convenient
to acquire in small children, they can reflect microbiota
also from the upper airways and are an approximation of
the true microbiological state of the lower airways [14].
Indirect detection methods such as determination of anti-
P. aeruginosa antibodies in serum of patients (serology)
have been shown to be useful for confirmation of chronic-
ally infected patients, who usually have very high antibody
values. In intermittently infected patients interpretation of
serology results can sometimes be difficult [15–20]. In
some patients antibody values can be above the cut-off
value for a positive test even when P. aeruginosa is not
isolated in respiratory samples. If such patients have signs
of an exacerbation or a progressive worsening of their
clinical status and lung function parameters, further
clinical investigations are due as it is possible that P. aer-
uginosa is not isolated because of technical difficulties
even though it is present in the lower airways. On such
occasions new methods that would be non-invasive and
could increase the possibility of earlier detection of in-
fection in children and non-sputum-producing CF pa-
tients would be beneficial.
The aim of our study was to assess and compare three
different approaches for earlier detection of P. aeruginosa
infection in children and adolescents with cystic fibrosis.
Used complimentarily with isolation from respiratory
samples, serology, lung function testing and a scoringsystem combining serology and spirometry were evaluated
and compared. Infection was confirmed with isolation of
P. aeruginosa from respiratory samples.
Methods
Study design and participants
There are currently 75 patients managed at the Center
for Children and Adolescents with CF at the University
Children’s Hospital in Ljubljana, Slovenia. Here, the
current standards of care [21, 22], standards for diagnosis
[23, 24] and guidelines for management and treatment of
lung infection [25] in CF patients are followed.
This study included 67 patients with an established
diagnosis of CF, who attended the Center between 2011
and 2015. A diagnosis of CF was made according to the
current published guidelines and was confirmed if a pa-
tient had two positive sweat tests on two occasions and
two disease causing mutations of the CFTR gene deter-
mined [23, 24].
Ethics approval for the study was granted by the
Slovenian National Ethics Committee and written consent
from the patient, parents, or caregivers was acquired
before enrollment. The patients were seen at regular 3-
monthly out-patient visits, yearly check-ups and at exacer-
bations. At all visits the clinical status and spirometry (in
patients older than 5 years or younger, if able to perform
the test) were evaluated and respiratory samples for
microbiological isolation were obtained. Serum for
measuring P. aeruginosa antibodies was collected sim-
ultaneously with clinical measurements and microbio-
logical sampling at yearly check-ups and at exacerbations.
In all patients at least two consequent serum samples
for the detection of anti-P. aeruginosa antibodies were
collected, one at the inclusion and the other at the end
of the study. On the mean 3.8 (SD ± 1.2) serum samples
were collected per patient during the study. At the end
of the study the patients were clustered into three
groups regarding the modified Leeds criteria: never in-
fected (when P. aeruginosa had never been isolated),
intermittently infected (when P. aeruginosa had been
isolated in less than 50% of samples taken in 1 year)
and chronically infected (when P. aeruginosa had been
isolated in more than 50% of samples taken in 1 year)
[26]. The design of the study is presented in Fig. 1.
Materials
Respiratory samples for microbiological isolation were
obtained based on the patient’s ability to expectorate.
Sputum was the preferred sample. In young children and
patients unable to expectorate, induced sputum was
acquired. In very young children and babies, deep throat
aspirates were acquired. If a sample could not be acquired
in any of the above ways and infection with P. aeruginosa
was probable, BAL was taken during bronchoscopy.
Children and adolescents with CF in 
Slovenia (N = 75)
Children and adolescents with CF 
managed at the CF Center at the 
University Children's Hospital Ljubljana 
between 2011–2015 (N = 67)
Clinic visits between 2011–2015 
(N = 1092)
Visits with full clinical and laboratory




Visits with full clinical and laboratory 





4.spirometry (older than 5 years)
Exclussion criteria:
-diagnosed after January 
2015
-no consent to participate in 
the study
Fig. 1 Study design of the longitudinal prospective study of children
and adolescents with CF managed at the Center for Children and
Adolescents with Cystic Fibrosis at the University Children’s Hospital
in Ljubljana, Slovenia
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Ljubljana, deep throat aspirates instead of swabs are col-
lected in children unable to produce sputum or induced
sputum. The technique of taking a deep throat aspirate
is similar to the second part of acquiring an induced
sputum sample in small children [13]. The difference is
that no inhalation of hypertonic saline is done before-
hand. A sterile catheter is used. The suction catheter is
inserted into the pharynx. To minimize contamination
of the specimen with secretions from the oropharynx,
suction is applied to the catheter only after it has been
inserted into the pharynx and is discontinued before it is
withdrawn.
Respiratory samples were processed according to the
current valid guidelines [27]. Briefly, sputum samples
were initially homogenized by using dithiothreitol (Sputa-
sol, Oxoid, Basingstoke, UK). Samples were inoculated on
5% sheep’s blood agar, chocolate agar, MacConkey agar,
chromogenic agar for the detection of Staphylococcus aur-
eus, Burkholderia cepacia selective agar (BCC), Sabouraud
dextrose agar and incubated at 35 ± 1 °C for 48 h, with the
exception of Sabouraud agar and BCC which were incu-
bated for 7 and 5 days, respectively. Plates were examined
daily. MALDI-TOF mass spectrometry using Biotyper
Microflex LT and MALDI Biotyper 3.0 software (Bruker
Daltonik, Bremen, Germany) was used for identification
of isolates.Lung function was measured with standard spirometry
in patients over 5 years of age and in younger patients
who were able to perform the test. The forced expiratory
volume in one second percent predicted value for age,
gender, and height (FEV1%) was used as a determinant
of lung function, based on Zapletal spirometry pediatric
reference values [28].
A Pseudomonas-CF-IgG test (Statens serum Institut,
Denmark, Art. No. 64742) was used for the quantitative
measurement of IgG antibody values of P. aeruginosa in
human serum samples. The antigens used to coat an
enzyme-linked immunoassay (ELISA) plate were a mix-
ture of antigens from P. aeruginosa serotypes O-1 to
O-17, which are the most commonly isolated serotypes
in respiratory samples of CF patients [15, 16]. All
serum samples of CF patients were tested in duplicates.
As required by the manufacturer, a standard curve in a
range of 0 to 50 ELISA units with standard pooled hu-
man antiserum diluted to 1:2.000 defined as 50 ELISA
units was used to measure the P. aeruginosa IgG con-
centration in CF patient samples.
Statistical analysis
IBM SPSS version 22 was used for statistical analysis.
Pearson’s correlation and the chi-square test were used
to calculate the correlation between results of serology,
spirometry and the combination of serology and spirom-
etry and the results of P. aeruginosa isolation. Receiver
operator characteristics curves (ROC curves) were con-
structed for all three approaches and cut-off values de-
termined. The area under the curve (AUC), sensitivity,
specificity, positive predictive value (PPV), and negative
predictive value (NPV) were calculated. Binary logistic
regression analysis was used to calculate the odds ratio
(OR), 95% confidence intervals (CI) and P values.
Results
The study group included 67 patients with a confirmed
diagnosis of CF. 29 (43%) patients were female and 38
(57%) male. Their mean age was 10.5 years (SD ± 5.9,
range 0.3–23.1 years). At the end of the study they were
clustered into three groups regarding the modified Leeds
criteria. There were no statistically significant differences
according to the number of participants, their gender
and their mean age between groups of never and intermit-
tently infected patients (N = 29 vs. N = 32; male:female
ratio 17:12 vs. 16:16; age: M = 8.93 vs. 10.63 years). There
were less participants in the chronically infected group
and their mean age was higher (N = 6; M = 19.59 years;
male:female ratio 2:4).
A total of 1092 clinic visits were conducted during the
4 years of the study. The data from the visits was consid-
ered complete if it included all the clinical parameters,
the result of isolation of P. aeruginosa from the
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old enough to perform spirometry, the value of FEV1%
predicted. Data from 242 visits was eligible for further
study. At 177 of the 242 visits lung function could also be
measured. From the 242 respiratory samples P. aeruginosa
was isolated in 52 (21.5%) samples. To evaluate the ac-
curacy of the used diagnostic approaches to predict P.
aeruginosa infection, ROC curves were constructed for
serology, spirometry and the combination of serology
and spirometry (Fig. 2a, b and c).
Cut-off values were specified from the ROC curves
using the optimal intersection of specificity and sensi-
tivity. Based on the data, the cut-off point for serology
was at 2.96 ELISA units, which was the same as recom-
mended by the manufacturer of the test. Based on the
ROC curve for spirometry the FEV1% cut-off value was
at 70%. When analyzing results of the combination of
serology and spirometry three different outcomes were
possible: normal serology and spirometry (ELISA < 2.96
EU and FEV1 > 70%), abnormal serology or spirometry
(ELISA > 2.96 EU or FEV1 < 70%), or abnormal serology
and spirometry (ELISA > 2.96 EU and FEV1 < 70%).
When serology and spirometry were normal the result
was marked as 0, when either serology or spirometry
were abnormal the result was marked as 1, and when
both were abnormal the result was marked as 2. The
possible outcomes and scores and their correlation with
P. aeruginosa isolation from respiratory samples are
presented in Table 1.
The AUC of the ROC curves, sensitivity, specificity,
PPV and NPV of the in the study used diagnostic
approaches to predict P. aeruginosa infection were cal-
culated. Serology had the highest AUC (0.81), sensitivity
(0.80) and NPV (0.93). It was followed by the combin-
ation of serology and spirometry with an AUC of 0.70
and the highest specificity of all of the three used
methods (0.90). The NPV was also high (0.79). Spirometry
alone had the lowest AUC (0.61), but high specificity
(0.83) and a NPV of 0.71. The data for all three used
approaches are presented in Table 2.
Pearson’s correlation was used to define the correl-
ation between serology and spirometry and isolation of
P. aeruginosa from the collected respiratory samples.
To evaluate the correlation between the combination of
serology and spirometry and isolation of P. aeruginosa
the chi-square test was used. A significantly positive
correlation between serology and the combination of
serology and spirometry and P. aeruginosa isolation
was confirmed (P < 0.01 for both). There was a signifi-
cantly negative correlation between spirometry and
isolation of P. aeruginosa (P < 0.05). A higher value of
serology or a higher score on the combined test and a
lower value of FEV1% predicted correlated with a
higher possibility of P. aeruginosa isolation.Binary logistic regression analysis was performed to
evaluate the predictive value of each of the used ap-
proaches for possible P. aeruginosa isolation. If the value
of serology was over 2.96, there was a 83.3% chance that
P. aeruginosa would be isolated (P < 0.01). If the FEV1%
predicted value was below 70% there was a 72.6% possibil-
ity that P. aeruginosa would be isolated (P < 0.05). If the
FEV1% predicted was under 70% or serology over 2.96
ELISA units there was a 73.4% chance of P. aeruginosa be-
ing isolated (P < 0.01). An increase of serology for 1 ELISA
unit increased the possibility of P. aeruginosa isolation 1.6
times. A fall in FEV1 for 10% increased the possibility of
P. aeruginosa isolation 9.8 times. An increase in the score
of the combination of serology and spirometry increased
the possibility of P. aeruginosa isolation 0.15 times. The
results of binary logistic regression analysis of the used
approaches associated with P. aeruginosa isolation are
presented in Table 3.
The change in antibody values and a change in FEV1%
predicted during the study were also evaluated. When
assessing the changes of serology and lung function over
time in individual patients, dynamics of both could be
seen. The dynamics in serology and spirometry over time
in association with P. aeruginosa isolation from two pa-
tients from the intermittently infected group is shown in
Fig. 3. The two patients are identical twins, carrying the
same two disease causing mutations of the CFTR gene.
They live in the same household and had sputum samples
acquired at the same time during the study. They were
13 years old at the inclusion into the study. P. aeruginosa
had been isolated in their sputum 2 years before inclusion
and had then been eradicated. In the first twin a fall in lung
function and a rise in antibody values were determined
12 months after inclusion into the study. At the same time
P. aeruginosa had been isolated and eradication therapy
started. Despite eradication therapy, which was considered
successful since P. aeruginosa had not been isolated in any
of the samples taken after the end of eradication, an eleva-
tion of antibody values continued and a further decline in
lung function followed especially after month 24 of the
study (Fig. 3a). After the end of the study P. aeruginosa
had been again intermittently isolated. In the second twin,
a year later, a rise of anti-P. aeruginosa antibodies together
with a fall in FEV1% predicted was observed. At the same
time P. aeruginosa was isolated (Fig. 3b).
When evaluating the data for all participants, a statis-
tically significant correlation of the change in FEV1%
predicted and the change in serology values over time
could not be confirmed (P > 0.05 for both). ROC curves
for the changes of serology and lung function over time
were constructed. The AUC for the change of serology
over time was 0.63, P < 0.02. For the change of FEV1%
predicted over time the AUC was 0.58, P > 0.05. The
ROC curves are presented in Fig. 4a, b.
Fig. 2 a ROC curve for serology. The cut-off point was specified
from the ROC curve using the optimal intersection of specificity
and sensitivity. Based on the drawn ROC curve, the cut-off point for
serology was at 2.96 ELISA units. b ROC curve for spirometry. The
cut-off point was specified from the ROC curve using the optimal
intersection of specificity and sensitivity. Based on the drawn ROC
curve, the cut-off point for spirometry was at 70% of FEV1 predicted
for gender, age and height. c ROC curve for the combination of
serology and spirometry. The cut-off point was specified from the
ROC curve using the optimal intersection of specificity and sensitivity.
Based on the drawn ROC curve, the cut-off point for the combination
of serology and spirometry was at 2.96 ELISA units and an FEV1 at 70%
of the predicted value for gender, age and height
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Chronic infection with P. aeruginosa is a known risk fac-
tor for higher morbidity and shorter survival of patients
with CF [1–4]. Early detection of infection can enable
the start of early eradication antibiotic therapy, which
can postpone or prevent chronic infection [5–7, 29, 30].
Culture-based detection of P. aeruginosa in respiratory
samples is the current gold standard for infection con-
firmation [27]. In children acquisition of sputum is not
always possible and induced sputum, deep throat swabs
or aspirates are used as a surrogate [10–12, 14]. Non
invasive methods that could complement isolation of P.
aeruginosa for earlier detection of infection in children
with CF would be beneficial.
According to this and the previously published studies
on P. aeruginosa serology [15–19], values of anti-P. aeru-
ginosa antibodies are important for evaluating the possi-
bility of P. aeruginosa infection in patients with CF. In the
presented study serology had high sensitivity (0.80) and a
good AUC (0.81) to predict P. aeruginosa infection.
A scoring system using the combination of anti-P. aeru-
ginosa serum antibody values and lung function measure-
ment, which has not been previously described, was
developed and assessed for the first time on a group of
children and adolescents with CF. The scoring system had
a high specificity of 0.90 and NPV of 0.79, thus enabling a
firm recognition of truly P. aeruginosa negative patients.
Complementing standard microbiological isolation with
the combination of serology and lung function measure-
ment could therefore be useful for ruling out infection
with P. aeruginosa as a cause of clinical deterioration. On
the other hand, detecting high values of anti-P. aeruginosa
antibodies in a patient with a decline of lung function
could be helpful for making further decisions on how to
manage the patient. The clinician would be encouraged to
proceed with more invasive methods for microbiological
sampling such as BAL, to acquire an adequate sample for
culture-based infection confirmation. The result of isola-
tion would then further influence the decision of starting
antibiotic therapy as this should be started only if P. aeru-
ginosa is isolated in the appropriate respiratory sample.
Table 1 Correlation between the scoring system using the combination of serology and spirometry and isolation of P. aeruginosa in
the patients enrolled in the study
Possible outcome for the combination
of serology and spirometry
Score Isolation of P. aeruginosa Number
of visitsNO YES
ELISA < 2.96 EU and FEV1 > 70% 0 70 7 N = 77
ELISA > 2.96 EU or FEV1 < 70% 1 45 30 N = 75
ELISA > 2.96 EU and FEV1 < 70% 2 10 15 N = 25
Number of samples N = 125 N = 52 N = 177
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has been constructed and is presented in Fig. 5. In this
study, the sensitivity and PPV of the scoring system to
predict P. aeruginosa infection were low (0.28 and 0.46,
respectively), which could cause positive patients to be
missed if the test was used alone and only on rare occa-
sions. The low sensitivity and PPV could be explained by
the used cut-off value for spirometry, the mean age and
the mean FEV1% predicted of our patients. An FEV1
below 70% was used as the cut-off value for predicting
the possibility of infection with P. aeruginosa based on
the calculated ROC curve for spirometry in this study.
The mean age of the included patients was 10.5 years
(SD ± 5.9, range 0.3–23.1 years) and the mean FEV1%
predicted 84.9% (SD ± 18.57, range 30–124%). It is ex-
pected that younger patients have better lung function.
This was also shown in our study. This could have been
the cause for the low number of patients with an FEV1%
under 70% which in turn caused a low number of truly
positive patients when assessing spirometry and the
combination of serology and spirometry for prediction
of P. aeruginosa infection.
The youngest population of CF patients still remains
challenging for diagnostics because they are not only un-
able to expectorate quality sputum or induced sputum
samples but are also unable to perform spirometry.
Other lung function testing methods such as the inter-
rupter technique could be used in these patients but are
not performed routinely because of technical difficulties
and limitations assessing FEV1. The lung clearance
index (LCI) as a lung function parameter derived from
the multiple-breath washout test has been assessed in
preschool children [31, 32] and could be useful in com-
bination with serology and microbiological isolation to
predict infection with P. aeruginosa in the future.Table 2 Comparison of the area under the curve, sensitivity, specific
spirometry and the combination of serology and spirometry for pred
Diagnostic test AUC Se
Serology 0.81 (SE 0.03, P < 0.02, CI 0.74–0.88)
Spirometry 0.61 (SE 0.05, P < 0.05, CI 0.52–0.70)
Serology and spirometry 0.70 (SE 0.04, P < 0.02, CI 0.61–0.78
Legend: AUC Area under the curve, SE Standard error, CI – 95% confidence interval, NPThere are various ways to determine whether a patient
is infected by specific microorganisms. All are based on
identification of an organism in specific microbiological
samples. Culture-based methods are currently the gold
standard for the detection of P. aeruginosa in respiratory
samples of CF patients [14, 27]. They are relatively inex-
pensive and standardized, and have the ability to identify
only viable organisms, which can then be tested for anti-
biotic susceptibility and stored for further study [12]. On
the other hand, culture-independent methods such as
quantitative real-time polymerase chain reaction (PCR),
16S rRNA sequencing, and next-generation sequencing
allow faster and precise identification of organisms if
used with large sequence databases, but it is possible for
non-viable organisms to also be detected [14, 33, 34].
Combination of serology with newer microbiological
methods such as real time PCR for P. aeruginosa detec-
tion directly in respiratory samples has been studied in
children with CF. In a study by da Silva et al. in 87 chil-
dren with CF, three P. aeruginosa detection methods
and their combinations were evaluated. P. aeruginosa
was detected using culture in 48.2% of patients, PCR in
60.9% and serology in 43.6%. The difference between the
used methods was not statistically significant, but PCR
in combination with serology implied to be most useful
for early P. aeruginosa detection [34]. Further studies
combining optimized quantitative real-time PCR proto-
cols with serology are needed to determine whether
such an approach enables more efficient and timely P.
aeruginosa detection.
In the presented study P. aeruginosa was in overall
isolated from 21.5% of samples. It was isolated from
43% of samples taken at visits in which the value of
anti-P. aeruginosa antibodies was over 2.96 ELISA
units, from 20.9% of samples taken at visits in whichity, positive and negative predictive values between serology,
iction of P. aeruginosa infection
nsitivity Specificity PPV NPV Number of visits
0.80 0.67 0.39 0.93 N = 242
0.29 0.83 0.43 0.71 N = 177
0.28 0.90 0.46 0.79 N = 177
V Negative predictive value, PPV Positive predictive value, N Number of visits
Fig. 3 a and b Dynamics of lung function and anti-P. aeruginosa antibody values over time in two identical twins from the intermittently infected
group. P. aeruginosa had been last isolated from their sputum 2 years before inclusion in the study. Eradication therapy had been completed and
was considered successful at that time according to the guidelines [25]. Isolation of P. aeruginosa, aggravation of lung function and a rise in
anti-P. aeruginosa antibodies was observed a year apart in the two twins. P. aeruginosa had been further intermittently isolated in both patients
after the end of the study
Table 3 Binary logistic regression analysis of serology, spirometry and their combination with P. aeruginosa isolation
Approach Odds ratio 95% Confidence interval P value
Serology 1.60 1.40–1.85 <0.01
Spirometry 0.98 0.96–1.00 <0.05
Combination of serology and spirometry 0.15 0.05–0.46 <0.01
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Fig. 4 a ROC curve for the change in serology values over time. Based on the joined data of all participants, an optimal cut-off value for the
change in serology over the time of the study could not be determined from the constructed ROC curve. The AUC for the change of serology
over time was 0.63. b ROC curve for the change in spirometry over time. Based on the joined data of all participants, an optimal cut-off value
for the change in spirometry over the time of the study could not be determined from the constructed ROC curve. The AUC for the change
of spirometry over time was 0.58
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Fig. 5 A proposed algorithm for the evaluation of the combination of serology and spirometry for assessing the possibility of P. aeruginosa
infection. Results of serology and spirometry should always be interpreted together with the results of culture-based detection of P. aeruginosa in
respiratory samples. The decision on starting antibiotic therapy should be based on the results of a positive culture and positive indirect methods
should encourage the clinician to continue/repeat microbiological investigations. Legend: normal serology and spirometry;
abnormal serology and normal spirometry; normal serology and abnormal spirometry; abnormal serology and spirometry
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and from 14.7% of samples taken at visits in which ei-
ther serology was over 2.96 ELISA units or FEV1% was
under 70% predicted. If used without culture, serology
would have overestimated the number of infections. In
this study spirometry and the combination of serology
and spirometry closely related the number of positive
respiratory samples and estimated the number of in-
fected patients well.
Conclusions
The challenge of detecting infection with P. aeruginosa
in the pediatric CF population as early as possible re-
mains. Laboratory diagnostic methods are best inter-
preted together with the clinical state of the patient. It
is hoped that combining new microbiological and
physiological methods together with precise clinical ob-
servation on larger study groups will yield a good solu-
tion. It was the aim of the presented study to provide
an approach that would enable the physician to be
more vigilant. The results show that serology, spirom-
etry and the combination of both can be a useful com-
plementary approach for earlier P. aeruginosa infection
detection in children with cystic fibrosis when used to-
gether with standard culture-based methods for infec-
tion confirmation. A change in serology, spirometry or
both could alert the physician of a possible infectionwith P. aeruginosa. Consequently diagnostic procedures
for direct detection/isolation of P. aeruginosa should be
intensified, finally enabling an earlier start of targeted
treatment in patients in whom the results of isolation
would confirm infection.
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